---
title: "Stocks of Eli Lilly and Novo plunged after Medicare excluded weight-loss drugs from coverage. Trump administration's new policies omitted them."
description: "On Friday, the Trump administration announced finalized Medicare and Medicaid policies, causing Eli Lilly stock to drop. The exclusion of weight-loss drugs led to a dive in Eli Lilly and Novo stocks. "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/234617274.md"
published_at: "2025-04-04T22:52:16.000Z"
---

# Stocks of Eli Lilly and Novo plunged after Medicare excluded weight-loss drugs from coverage. Trump administration's new policies omitted them.

> On Friday, the Trump administration announced finalized Medicare and Medicaid policies, causing Eli Lilly stock to drop. The exclusion of weight-loss drugs led to a dive in Eli Lilly and Novo stocks. The decision had significant effects on the market, with Eli Lilly experiencing a noticeable decline in stock value.

On Friday, the Trump administration announced finalized Medicare and Medicaid policies, causing Eli Lilly stock to drop. The exclusion of weight-loss drugs led to a dive in Eli Lilly and Novo stocks. The decision had significant effects on the market, with Eli Lilly experiencing a noticeable decline in stock value.

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)
- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Novo files patent suit against Hims & Hers over Wegovy knockoffs | Novo files patent suit against Hims & Hers over Wegovy knockoffs | [Link](https://longbridge.com/en/news/275316277.md) |
| Novo Nordisk A/S repurchases units for DKK 222 million | Novo Nordisk A/S has repurchased 750,000 B shares for approximately DKK 222 million at an average price of 296.40 DKK pe | [Link](https://longbridge.com/en/news/275315124.md) |
| Novo Nordisk Launches Weight Loss Pill Across US | Novo Nordisk Launches Weight Loss Pill Across US | [Link](https://longbridge.com/en/news/274912821.md) |
| Novo Nordisk CEO Mike Doustdar Plans To Bring "Wegovy High-Dose" To Market As Soon As Possible - CNBC Interview | NOVO NORDISK CEO MIKE DOUSTDAR: PLANS TO BRING "WEGOVY HIGH-DOSE" TO THE MARKET AS SOON AS POSSIBLE- CNBC INTERVIEW | [Link](https://longbridge.com/en/news/274884174.md) |
| Novo Nordisk Says FDA Approves Ozempic Pill, Set to be Available in US in Q2 | Novo Nordisk Says FDA Approves Ozempic Pill, Set to be Available in US in Q2 | [Link](https://longbridge.com/en/news/274849748.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.